| Item Type | Name |
|
Concept
|
Brain
|
|
Concept
|
Blood-Brain Barrier
|
|
Concept
|
Brain-Derived Neurotrophic Factor
|
|
Concept
|
Brain Neoplasms
|
|
Academic Article
|
Phenotype of CD4+ T cell subsets that develop following mouse facial nerve axotomy.
|
|
Academic Article
|
The presence of IL-17A and T helper 17 cells in experimental mouse brain tumors and human glioma.
|
|
Academic Article
|
Recent developments on immunotherapy for brain cancer.
|
|
Academic Article
|
IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival.
|
|
Academic Article
|
CD4+ T cell-mediated neuroprotection is independent of T cell-derived BDNF in a mouse facial nerve axotomy model.
|
|
Academic Article
|
IL-10 within the CNS is necessary for CD4+ T cells to mediate neuroprotection.
|
|
Academic Article
|
Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors.
|
|
Academic Article
|
Short hairpin RNA-mediated fibronectin knockdown delays tumor growth in a mouse glioma model.
|
|
Academic Article
|
The expression of BST2 in human and experimental mouse brain tumors.
|
|
Academic Article
|
Targeting Tregs in Malignant Brain Cancer: Overcoming IDO.
|
|
Academic Article
|
Blood-brain barrier permeable gold nanoparticles: an efficient delivery platform for enhanced malignant glioma therapy and imaging.
|
|
Academic Article
|
Heme oxygenase-1 protects regulatory T cells from hypoxia-induced cellular stress in an experimental mouse brain tumor model.
|
|
Academic Article
|
Nanoparticle-programmed self-destructive neural stem cells for glioblastoma targeting and therapy.
|
|
Academic Article
|
Depletion of myeloid-derived suppressor cells during interleukin-12 immunogene therapy does not confer a survival advantage in experimental malignant glioma.
|
|
Academic Article
|
Fibrin-binding, peptide amphiphile micelles for targeting glioblastoma.
|
|
Academic Article
|
Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors.
|
|
Academic Article
|
Dendritic Cell-Based Vaccines that Utilize Myeloid Rather than Plasmacytoid Cells Offer a Superior Survival Advantage in Malignant Glioma.
|
|
Academic Article
|
The role of IDO in brain tumor immunotherapy.
|
|
Academic Article
|
Advanced age negatively impacts survival in an experimental brain tumor model.
|
|
Academic Article
|
CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells.
|
|
Academic Article
|
Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives.
|
|
Academic Article
|
Non-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4/PD-L1 inhibition in mouse glioblastoma.
|
|
Academic Article
|
Therapeutic Hypothesis Testing With Rodent Brain Tumor Models.
|
|
Academic Article
|
A Dendritic Cell-Targeted Adenoviral Vector Facilitates Adaptive Immune Response Against Human Glioma Antigen (CMV-IE) and Prolongs Survival in a Human Glioma Tumor Model.
|
|
Academic Article
|
Imaging tryptophan uptake with positron emission tomography in glioblastoma patients treated with indoximod.
|
|
Academic Article
|
Management of glioblastoma in elderly patients.
|
|
Academic Article
|
Newly Diagnosed Glioblastoma: A Review on Clinical Management.
|
|
Academic Article
|
The interplay among psychological distress, the immune system, and brain tumor patient outcomes.
|
|
Academic Article
|
A retrospective survival analysis of Glioblastoma patients treated with selective serotonin reuptake inhibitors.
|
|
Academic Article
|
Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma.
|
|
Academic Article
|
Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies.
|
|
Academic Article
|
Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank.
|
|
Academic Article
|
Tryptophan metabolism in brain tumors - IDO and beyond.
|
|
Academic Article
|
Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug.
|
|
Academic Article
|
Mid-life epigenetic age, neuroimaging brain age, and cognitive function: coronary artery risk development in young adults (CARDIA) study.
|
|
Academic Article
|
Circadian Regulator CLOCK Drives Immunosuppression in Glioblastoma.
|
|
Academic Article
|
A systematic review of pharmacologic treatment efficacy for depression in older patients with cancer.
|
|
Academic Article
|
Identification and Characterization of a Novel Indoleamine 2,3-Dioxygenase 1 Protein Degrader for Glioblastoma.
|
|
Grant
|
The interaction of IDO and Tregs Leads to Immunosuppression in Glioma
|
|
Grant
|
The interaction of IDO and Tregs Leads to Immunosuppression in Glioma
|
|
Grant
|
Aging, immunosenescence and glioblastoma
|
|
Academic Article
|
Advanced Age in Humans and Mouse Models of Glioblastoma Show Decreased Survival from Extratumoral Influence.
|
|
Academic Article
|
Age-stratified comorbid and pharmacologic analysis of patients with glioblastoma.
|